Aptevo Therapeutics Inc (NASDAQ:APVO) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $10.50 for the company and are anticipating that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 158 out of 255 based on the ratings given to related companies.
Several equities research analysts have issued reports on the company. ValuEngine lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 29th. Piper Jaffray Companies lifted their price target on Aptevo Therapeutics from $6.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, May 10th. Finally, Roth Capital assumed coverage on Aptevo Therapeutics in a research note on Wednesday, April 11th. They set a “buy” rating and a $12.00 price target for the company.
APVO stock traded up $0.13 during mid-day trading on Friday, hitting $5.09. 52,900 shares of the stock were exchanged, compared to its average volume of 180,702. The company has a quick ratio of 4.39, a current ratio of 4.47 and a debt-to-equity ratio of 0.20. Aptevo Therapeutics has a 12 month low of $1.15 and a 12 month high of $6.35. The firm has a market cap of $112.71 million, a P/E ratio of -3.33 and a beta of 0.74.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.07). The business had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $3.37 million. research analysts expect that Aptevo Therapeutics will post -2.63 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC increased its holdings in shares of Aptevo Therapeutics by 215.4% in the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock worth $130,000 after buying an additional 27,079 shares during the period. Spark Investment Management LLC increased its holdings in shares of Aptevo Therapeutics by 82.8% in the first quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock worth $423,000 after buying an additional 58,600 shares during the period. Virtu Financial LLC purchased a new position in shares of Aptevo Therapeutics in the fourth quarter worth about $690,000. Park West Asset Management LLC purchased a new position in shares of Aptevo Therapeutics in the first quarter worth about $604,000. Finally, Alambic Investment Management L.P. purchased a new position in shares of Aptevo Therapeutics in the first quarter worth about $646,000. Hedge funds and other institutional investors own 34.16% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.